ARCT
Arcturus Therapeutics Holdings Inc.
NASDAQ · Healthcare · Biotechnology · US
$16.03
−5.32%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$16.64
From 52W high−30.79%
Volume816748.00
Market cap$455.62M
P/E (TTM)—
P/S (TTM)19.1x
Div yield—
Key dataSep 18, 2026
Open
$16.64
From 52W high
−30.79%
Volume
816748.00
Market cap
$455.62M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.5x
P/E (TTM)
—
RSI (14)
65.7
MomentumView details →
1D Return
−5.32%
YTD Return
+167.29%
SummaryUpdated Jun 1, 2026
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is a biotechnology company founded in 2013 and headquartered in San Diego, California. The company specializes in developing RNA-based medicines, focusing on vaccines for infectious diseases and therapeutic treatments for rare genetic disorders affecting the liver and respiratory system. Since going public in 2013, Arcturus has evolved from an early-stage biotech into a clinical-stage company with multiple programs in human trials and its first approved product - a COVID-19 vaccine launched in Japan.
Similar companies
Latest newsMore news →
Arcturus Therapeutics announced it will host a virtual presentation on September 23, 2026, to provide an overview of the ARCT-810 Phase 2 clinical program for Ornithine transcarbamylase (OTC) deficiency and its mRNA liver therapeutics platform.2d agoArcturus Therapeutics reported a second-quarter loss of $0.84 per share, beating the Zacks Consensus Estimate of a loss of $1.07, and compared to a loss of $0.34 per share a year ago.45d agoArcturus Therapeutics regained global rights to its KOSTAIVE COVID-19 vaccine and self-amplifying mRNA platform after ending its collaboration with CSL Seqirus.45d ago